The work, led by Kui Deng, Yu-ming Chen, and colleagues at Sun Yat-sen University together with collaborators at the Human Metabolomics Institute, Westlake University-affiliated Hangzhou First People’s Hospital, Shanghai Jiao Tong University School of Medicine, and Ningbo University, is described by its authors as the first population-based study to systematically investigate longitudinal, prospective associations between serum proteins and serum metabolites. Rather than measuring both molecular layers at a single time point, the team followed participants across multiple clinic visits, allowing them to ask whether the level of a circulating protein at one visit predicted the level of a metabolite at a later one, a design that strengthens the case for directional, temporal relationships rather than mere correlation.

The foundation of the analysis is the Guangzhou Nutrition and Health Study, an ongoing population cohort of middle-aged and elderly adults. For this investigation, the researchers assembled data from 485 participants with an average age of 56.9 years, plus or minus about 4.5 years. Serum proteome measurements, covering 411 proteins, were available at three cohort visits, yielding 1,455 protein profiles in total. Serum metabolome measurements, covering 196 metabolites, were collected at four visits spread across 12.3 years of follow-up, producing 1,940 metabolite profiles. This repeated-measures architecture is what distinguishes the study from earlier cross-sectional surveys: each participant serves, in effect, as their own temporal control, and the passage of time between visits becomes an explicit part of the statistical model.

Methodologically, the team divided participants into a discovery set of 402 individuals and a validation set of 83, a split designed to guard against spurious findings. To interrogate every possible protein-metabolite combination, they applied linear mixed-effects models, a statistical framework well suited to longitudinal data because it can accommodate the nested structure of repeated measurements within individuals while adjusting for within-person correlation. Each pairwise protein-metabolite combination was tested for a prospective association, in which protein levels measured at one visit were related to metabolite levels measured subsequently. Given the enormous number of tests inherent in such a pairwise mapping, the researchers controlled the false discovery rate, a standard safeguard in high-dimensional omics research that limits the expected proportion of false positives among declared discoveries.

Out of this systematic screen emerged 53 longitudinal prospective associations linking 28 proteins to 34 metabolites. These pairs constitute what the investigators call protein-metabolite axes: recurring, temporally ordered relationships in which circulating proteins appear to anticipate changes in the small-molecule chemical traffic of the blood. The identity of the linked molecules spans well-known metabolic territory, and the fact that the associations were confirmed in a held-out validation subset lends weight to their robustness. Because metabolites are often the downstream products or substrates of protein-driven enzymatic activity, such axes plausibly represent readable signatures of physiological regulation in action.

But mapping the axes was only the first step. The researchers then asked whether the proteins and metabolites involved were themselves connected to metabolic outcomes. They examined 13 metabolic traits, including standard clinical measures such as body mass index, waist circumference, waist-to-hip ratio, systolic and diastolic blood pressure, glycated hemoglobin A1c, Homeostatic Model Assessment for Insulin Resistance, total cholesterol, high-density and low-density lipoprotein cholesterol, and triglycerides. They also examined four metabolic diseases: type 2 diabetes, metabolic syndrome, hypertension, and obesity. Using linear mixed-effects models for the traits and logistic regression for the disease outcomes, the team uncovered a dense web of associations: 91 links between proteins and metabolic traits, 44 between proteins and metabolic diseases, 104 between metabolites and metabolic traits, and 7 between metabolites and metabolic diseases.

The most consequential findings came from stitching these layers together. Through mediation analysis, a statistical technique that tests whether a third variable explains the pathway between an exposure and an outcome, the researchers identified 17 protein-metabolite-metabolic trait or disease pathways. In these pathways, a circulating protein is prospectively associated with a metabolite, and that metabolite in turn carries the association forward to a clinical trait or disease. Such chains suggest a mechanistic logic: a protein influences a small-molecule mediator, which then contributes to disordered metabolism. If validated in independent populations and experiments, these axes could point to intervention targets, since metabolites lying on a causal path between a protein and a disease represent a potential point where the chain could be interrupted.

The four diseases under study are among the most burdensome chronic conditions worldwide, and all four are tightly intertwined with lipid and glucose metabolism. Type 2 diabetes, characterized by progressive insulin resistance and dysregulated glycemic control, metabolic syndrome, a cluster of central obesity, elevated blood pressure, and abnormal blood lipids, hypertension, and obesity together account for an enormous share of cardiovascular and renal morbidity. By anchoring molecular associations to these clinically meaningful endpoints, the study moves beyond cataloging molecular correlations and speaks directly to the biology of disease risk. The inclusion of insulin resistance measures such as HOMA-IR alongside conventional lipid panels reflects an attempt to capture metabolic dysfunction in its several dimensions rather than relying on any single marker.

The researchers are careful to frame the identified axes as potential rather than proven intervention targets. Longitudinal prospective association, even with mediation evidence, does not by itself establish causation, and the observed pathways could reflect confounding by diet, medication use, inflammation, or organ function that neither proteins nor metabolites fully capture. The cohort, while well characterized, consists of middle-aged and elderly Chinese adults, and the generalizability of specific protein-metabolite pairings to other populations and age groups will require replication. The authors note that the work was supported by the National Natural Science Foundation of China, the Natural Science Foundation of Guangdong Province, the Key Research and Development Program of Guangzhou, and the 5010 Program for Clinical Researches of Sun Yat-sen University, and they acknowledge the participants of the Guangzhou Nutrition and Health Study as well as the university’s high-performance computing platform.

Even with those caveats, the significance of the resource is considerable. Population-scale efforts in genomics have flourished in part because DNA is stable and easy to measure repeatedly; the proteome and metabolome are far more dynamic, sensitive to fasting state, circadian rhythm, and recent meals, which makes long-term longitudinal mapping technically and logistically demanding. By demonstrating that such mapping is feasible at population scale, and by releasing a catalog of temporally ordered protein-metabolite associations linked to metabolic outcomes, the study provides a scaffold that other researchers can build upon, whether through Mendelian randomization, experimental perturbation in cell and animal models, or integration with genetic and gut microbiome data. The authors suggest that the protein-metabolite axes they describe may serve as potential targets for intervention to enhance metabolic health, and the 17 pathways they delineated offer a concrete starting point for that longer scientific agenda, one in which the slow molecular conversations conducted in the bloodstream are finally being transcribed and translated into clinical insight.

Subject of Research: Longitudinal mapping of serum protein-metabolite associations and their role in metabolic health

Article Title: Longitudinal mapping of the blood proteome to blood metabolome reveals the role of the protein-metabolite axes in metabolic health

Article References: Deng, K., Zhou, K., Xiao, C., Lu, Z., Ru, D., Wang, X., Xi, Y., Jia, S., Huang, F., Chen, T., Zheng, J.-S., Xie, G., & Chen, Y.-M. (2026). Longitudinal mapping of the blood proteome to blood metabolome reveals the role of the protein-metabolite axes in metabolic health. Genome Medicine. https://doi.org/10.1186/s13073-026-01775-y

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01775-y

Keywords: proteome, metabolome, metabolic health, type 2 diabetes, metabolic syndrome, hypertension, obesity, longitudinal cohort, linear mixed-effects model, protein-metabolite axes, biomarkers, metabolomics

The analysis, conducted according to PRISMA 2020 standards, drew its evidence from the major Phase 3 programs that defined the modern incretin era: SURMOUNT, testing tirzepatide; STEP, testing injectable semaglutide; SCALE, testing liraglutide 3.0 mg; and OASIS, testing oral semaglutide. From an initial pool of 878 records, independent reviewers narrowed the field to 19 randomized controlled trials meeting strict criteria, including a minimum duration of 12 weeks and standardized body composition or nutritional laboratory measurements. High-potency therapy was defined as any agent or dose producing at least 10 percent mean total body weight reduction, a threshold met by all tirzepatide doses, injectable semaglutide at 1.0 mg or above, and oral semaglutide 50 mg. Liraglutide 3.0 mg was classified as a moderate-potency comparator but retained because the SCALE program remains the only Phase 3 dataset with longitudinal pancreatic enzyme measurements.

The mechanistic foundation of the findings lies in the sheer magnitude of caloric suppression these drugs produce. Once-daily oral semaglutide 50 mg reduced energy intake by a relative 39.20 percent by week 20, translating to a deficit of roughly 1009 kilojoules, about 241 calories, during a single ad libitum lunch compared with placebo. Across the synthesized trials, metabolic models estimated daily energy deficits reaching 1200 kilocalories from baseline, while tirzepatide 15 mg produced a consistent 348.40 kilocalorie per day reduction. Meta-analysis of continuous intake data confirmed this suppression was statistically robust. Critically, these deficits occurred alongside shifts in food preference: participants on tirzepatide showed significant decreases in 10 of 12 food preference categories, blunting desire for high-fat and high-sugar items. The hedonic blunting that helps patients eat less may simultaneously suppress the biological hunger signals that normally correct for emerging nutrient gaps.

Body composition data revealed a second dimension of concern. Across drug classes, fat-free mass, the non-adipose component of body weight that includes muscle, bone, organs, and fluids, declined significantly. Tirzepatide 15 mg was associated with a mean fat-free mass reduction of 1.60 kg, representing 14.30 percent of total weight lost, while semaglutide 1.0 mg produced a 0.80 kg decline constituting 11.60 percent of weight reduction. The researchers emphasize that fat-free mass is not synonymous with skeletal muscle mass, and only one mechanism-of-action study reported appendicular lean mass as a muscle proxy. Even so, the proportional loss of lean tissue raises the prospect of sarcopenic obesity, a condition combining reduced muscle mass with metabolic dysfunction. The risk is sharpened by the finding that 7.26 percent of participants crossed a body mass index below 22 kg/m2, a threshold at which clinical protocols recommend modifying intake to prevent physical frailty.

The contrast between clinical reporting and laboratory reality forms the analytical centerpiece of the review. Pooled analysis of MedDRA-coded malnutrition events across the SURMOUNT 1-4 trials produced a non-significant risk ratio of 2.38, suggesting standard adverse event capture missed most nutritional deterioration. Total lymphocyte count below 910 per microliter, a marker independently associated with impaired immune function, delayed wound healing, and increased infection susceptibility, appeared in 2.90 percent of active therapy participants, nearly double the placebo rate, with a statistically significant risk ratio of 1.64. Meanwhile, 0.38 percent of tirzepatide-treated participants reached an underweight classification during treatment, and investigator-reported vitamin deficiencies involving vitamin D, B12, and folate occurred in 0.99 percent, though none of the original protocols screened for these systematically at predetermined intervals.

Secondary metabolic stressors add another layer of physiological complexity. Pooled SCALE data documented a mean 31 percent increase in pancreatic lipase and 7 percent increase in amylase following liraglutide treatment, elevations that appeared early, persisted during therapy, were dose-independent, and reversed upon drug cessation. Although 12 cases of acute pancreatitis were confirmed in liraglutide arms, a 0.4 percent incidence, the positive predictive value of enzyme elevations alone was below 1 percent, indicating these biomarkers more likely represent subclinical pancreatic stress than acute inflammation. Whether comparable enzyme dynamics occur with tirzepatide or injectable semaglutide remains unknown, because neither the SURMOUNT nor STEP programs included pancreatic enzyme monitoring. Persistent subclinical pancreatic stress could theoretically introduce a malabsorptive component, potentially compromising fat-soluble vitamin status even in patients with adequate intake.

Individual variability in baseline physiology may determine who is most vulnerable. Deep-phenotyping research describes a ‘Calories to Satiation’ trait ranging from 140 to 2166 kilocalories among adults with obesity, and high-potency incretins may amplify this gut-brain axis signal to its maximum effect. People who already reach satiation at low caloric intakes could ‘overshoot’ intended restriction, a concern compounded by sex differences, since women generally reach satiation at lower energy intakes than men. In trials with predominantly female enrollment, such as SURMOUNT-1 at 67 percent and STEP 1 at 74 percent female, the observed magnitude of lean mass loss may partly reflect this lower baseline caloric threshold. Bone health introduces a further unmeasured dimension: rapid weight loss removes the mechanical loading stimulus that sustains bone mineral density in obesity, and bariatric surgery studies document significant bone loss within 12 to 24 months. No included trial measured bone density, leaving the skeletal consequences of drug-induced weight loss entirely unquantified.

To translate these findings into clinical practice, the researchers propose a Tiered Stepped-Care Algorithm built on the 1200 kilocalorie daily deficit as the mechanistic anchor. Step one mandates baseline screening for albumin, total lymphocyte count, and vitamin D to identify pre-existing vulnerabilities. Step two requires periodic monitoring of the deficit threshold alongside body composition shifts to detect excessive lean mass attrition. Step three activates intensive intervention, with immediate referral for Medical Nutrition Therapy, when serum albumin falls below 3.3 g/dL or total lymphocyte count drops below 910 per microliter. The framework mirrors nutritional oversight long considered standard for bariatric surgery patients, a population whose weight loss trajectories are comparable in magnitude to those produced by maximum-dose tirzepatide, which achieved 22.5 percent total body weight loss over 72 weeks in SURMOUNT-1.

The authors acknowledge important limitations. The original Phase 3 programs were designed to demonstrate weight loss efficacy and cardiometabolic safety, not nutritional outcomes, so reliance on post-hoc analyses likely underestimates true malnutrition prevalence. The 12-week minimum duration criterion may have excluded shorter mechanistic studies, the predominantly East Asian population in SURPASS-AP-Combo, with lower baseline body mass indices, limits generalizability to Western cohorts, and publication bias could not be excluded from secondary endpoints. Quality assessment using the Cochrane Risk-of-Bias tool found low risk across all major domains for the included programs, and Egger regression detected no significant publication bias for the primary outcome. Future trials, the researchers argue, should incorporate pre-specified dual-energy X-ray absorptiometry monitoring, serum micronutrient panels, fecal elastase testing, head-to-head comparisons in adults aged 65 and older with sarcopenia and bone density as co-primary outcomes, and follow-up of at least two years. Sustained weight reduction remains a legitimate therapeutic goal, the analysis concludes, but the data suggest it should no longer be pursued without the nutritional surveillance needed to protect the physiological integrity of the millions of patients now taking these medications.

Subject of Research: Systematic review and meta-analysis of malnutrition risk, energy restriction, and lean mass loss in high-potency incretin therapy

Article Title: A Systematic Review and Meta‐Analysis of Malnutrition and Metabolic Failure in High‐Potency Incretin Therapy

Article References: Ampofo, E., Apprey, C., Amoako, M., & Turkson, F. D. (2026). A Systematic Review and Meta‐Analysis of Malnutrition and Metabolic Failure in High‐Potency Incretin Therapy. Obesity Science & Practice, 12(5), Article e70188. https://doi.org/10.1002/osp4.70188

Image Credits: AI Generated

DOI: 10.1002/osp4.70188

Keywords: incretin therapy, semaglutide, tirzepatide, liraglutide, malnutrition, fat-free mass, weight loss, obesity, GLP-1 receptor agonists, nutritional monitoring, sarcopenia, meta-analysis

Metabolic syndrome is a cluster of interrelated risk factors—abdominal obesity, elevated triglycerides, low high-density lipoprotein cholesterol, high blood pressure, and elevated fasting glucose—that together markedly increase the likelihood of type 2 diabetes, cardiovascular disease, and stroke. Clinically, it is often treated as a condition of the overweight and sedentary, and screening strategies frequently hinge on waist circumference. Yet previous research, including a meta-analysis showing that obstructive sleep apnea predicts metabolic syndrome independently of obesity, has hinted that the airway and the metabolism are entangled in ways that body size alone cannot explain.

The new study, led by Yuko Kato of the Department of Public Health at Juntendo University Graduate School of Medicine, together with Ai Ikeda, Hadrien Charvat, Kiyohide Tomooka, Koutatsu Maruyama, Isao Saito, and senior author Takeshi Tanigawa, set out to disentangle that relationship. The team drew on participants of the Toon Health Study, an ongoing community-based cohort in Ehime, Japan, and focused on 647 adults who, at baseline, had neither metabolic syndrome nor abdominal obesity, defined by Japanese and Asia-Pacific criteria as a waist circumference below 90 centimeters in men and below 80 centimeters in women. This deliberately lean starting population allowed the researchers to isolate the effect of nighttime oxygen fluctuations from the confounding influence of central fat.

To quantify intermittent hypoxia—the recurring cycles of falling and recovering blood oxygen that occur when the upper airway collapses during sleep—the researchers used overnight pulse oximetry and calculated the 3% oxygen desaturation index, or ODI, the number of times per hour that blood oxygen saturation drops by at least 3%. A threshold of five desaturation events per hour separated participants into those with and without meaningful nocturnal intermittent hypoxia. The team then followed the cohort for a median of 5.0 years, reassessing metabolic syndrome and each of its components at the five-year follow-up survey using modified National Cholesterol Education Program Adult Treatment Panel III criteria adapted for Asian populations.

Because relatively rare outcomes and conventional logistic regression can inflate risk estimates, the investigators employed modified Poisson regression, a method that yields more directly interpretable risk ratios, with Firth-type penalization to stabilize estimates in the presence of sparse data. Critically, they stratified all analyses by age, comparing adults younger than 65 with those aged 65 and older—a decision grounded in prior evidence that the cardiovascular and metabolic hazards of sleep-disordered breathing appear to attenuate with advancing age, perhaps because older adults who survive with the condition represent a selected, more resilient population.

The results were striking in the younger stratum. Among adults under 65, those with a 3% ODI of five or higher had more than double the risk of developing metabolic syndrome over five years compared with their peers who breathed steadily through the night, with a risk ratio of 2.10 and a 95% confidence interval of 1.18 to 3.76. The pattern extended to individual components: nocturnal intermittent hypoxia conferred a 2.17-fold higher risk of newly developing abdominal obesity (95% CI 1.42–3.33), a 2.01-fold higher risk of low HDL cholesterol (95% CI 1.02–3.96), and a 2.41-fold higher risk of hypertriglyceridemia (95% CI 1.35–4.30). In the older age group, by contrast, no statistically significant association emerged between oxygen desaturation and incident metabolic syndrome or any of its components.

The component-level findings carry particular biological weight. Elevated triglycerides and reduced HDL cholesterol are the lipid fingerprints of metabolic dyslipidemia, and experimental work has long suggested a causal pathway: in lean mice, intermittent hypoxia alone induces hyperlipidemia, and in humans, nocturnal hypoxemia has been independently linked to dyslipidemia irrespective of obesity. Mechanistically, each cycle of desaturation and reoxygenation resembles ischemia-reperfusion injury at the tissue level, generating reactive oxygen species, activating inflammatory pathways, and stressing adipose tissue itself. Adipocytes respond by releasing pro-inflammatory cytokines and altered adipokine profiles, including disturbed leptin signaling, which in turn promotes hepatic very-low-density lipoprotein production and peripheral insulin resistance. Intermittent hypoxia also activates the sympathetic nervous system and the renin-angiotensin system, raising blood pressure and compounding cardiovascular strain.

Perhaps the most provocative result is the link between nighttime oxygen dips and the later emergence of abdominal obesity in people who began the study without it. This raises the question of directionality that has haunted the field for decades—the proverbial chicken-and-egg problem of whether visceral fat causes sleep apnea or sleep apnea cultivates visceral fat. By restricting the analysis to participants free of abdominal obesity at baseline, the study provides longitudinal support for the latter possibility: disordered nighttime breathing appears capable of initiating the central fat accumulation that defines the metabolic syndrome, rather than merely riding alongside it.

The age stratification adds an important nuance with clinical implications. If intermittent hypoxia accelerates metabolic deterioration primarily in midlife, then undiagnosed sleep-disordered breathing in younger, lean adults may represent a hidden reservoir of future cardiometabolic disease—one that current screening practices, which often target older or heavier patients, could easily miss. Pulse oximetry screening has known limitations, and the ODI is an imperfect proxy for full polysomnographic diagnosis, but the present findings suggest that a simple overnight oximetry measure may identify metabolically vulnerable individuals years before standard criteria flag them. Whether treating sleep-disordered breathing with continuous positive airway pressure can interrupt this trajectory remains debated; randomized evidence in metabolic syndrome has been mixed, and the authors note that earlier intervention, particularly in younger adults, may be where therapy has the greatest chance of altering risk.

The study’s strengths include its prospective design, its use of an objective physiological exposure measure rather than self-reported snoring, its rigorous adjudication of metabolic syndrome, and its focus on a population deliberately free of central adiposity. Limitations temper the conclusions: the cohort was community-based and Japanese, raising questions of generalizability to other ethnic groups in whom both obesity thresholds and sleep apnea prevalence differ; the five-year follow-up captured incident disease but not longer-term trajectories; and residual confounding by diet, alcohol, and detailed sleep habits cannot be excluded. The authors acknowledge support from JSPS KAKENHI grant 22H00496 and declare no competing interests. Still, the message is clear and increasingly well supported: the metabolic toll of ragged nighttime breathing does not require an expanded waistline to begin, and age is not merely a passive bystander but a decisive modifier of that risk. For millions of lean adults who snore, gasp, or desaturate nightly without knowing it, the oxygen monitor may see what the bathroom scale cannot.

Subject of Research: Association of nocturnal intermittent hypoxia with incident metabolic syndrome in non-obese Japanese adults

Article Title: Effects of nocturnal intermittent hypoxia on metabolic syndrome in Japanese adults without abdominal obesity

Article References: Kato, Y., Ikeda, A., Charvat, H., Tomooka, K., Maruyama, K., Saito, I., & Tanigawa, T. (2026). Effects of nocturnal intermittent hypoxia on metabolic syndrome in Japanese adults without abdominal obesity. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02228-7

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02228-7

Keywords: nocturnal intermittent hypoxia, metabolic syndrome, oxygen desaturation index, obstructive sleep apnea, abdominal obesity, dyslipidemia, hypertriglyceridemia, prospective cohort, Japanese adults, Toon Health Study, cardiometabolic risk, pulse oximetry

The research team began by examining peripheral blood from healthy human volunteers, stratified into young adults aged 18 to 40 and middle-aged adults aged 41 to 65. When natural killer cells were stimulated in the laboratory with the cytokine interleukin-15, a potent activator of NK cell activity, a striking sex-specific pattern emerged. Cells from middle-aged men expressed significantly lower levels of CD107a, a marker of degranulation that reflects the cell’s ability to release its cytotoxic payload, and produced markedly less interferon-gamma, the signature cytokine that coordinates antiviral and antitumor responses. In contrast, natural killer cells from middle-aged women performed comparably to those from young women across these functional readouts. Enzyme-linked immunosorbent assays of purified CD3-negative CD56-positive cells confirmed that the cytokine secretion deficit in middle-aged men was genuine and not an artifact of intracellular staining.

Surface receptor profiling added further nuance. The investigators measured a panel of receptors known to regulate natural killer cell development and function, including CD150, 2B4, CD84, CD319, NKG2A, NKG2D, CD48, Ly9, Ly108, Tim-3, and CD69. Most of these were unchanged between age groups, but young male donors displayed higher expression of CD48, a ligand involved in activating signals. The authors conclude that reduced cytotoxic function and diminished cytokine production are defining characteristics of natural killer cells in middle-aged men, even in the absence of overt disease.

To dissect the mechanisms behind this human observation, the team turned to a mouse model, comparing 8-week-old young males with 48-week-old middle-aged animals, an age that corresponds roughly to human midlife. Consistent with prior work, the middle-aged mice were substantially heavier, with magnetic resonance imaging revealing elevated fat mass and enlarged epididymal and inguinal white adipose depots. Brown adipose tissue also increased in mass, but its thermogenic browning capacity was significantly diminished. Metabolic cage experiments painted a coherent picture of midlife metabolic decline: oxygen consumption, carbon dioxide production, respiratory exchange ratio, and whole-body energy expenditure all fell significantly, even though spontaneous activity levels were comparable between age groups. Food and water intake were actually reduced, underscoring that the adiposity of middle age reflects a fundamental shift in basal metabolism rather than simple overconsumption.

Flow cytometric analysis across the spleen, bone marrow, liver, peripheral blood, and adipose tissues revealed that natural killer cells were among the most affected immune populations. The relative proportion of NK cells dropped significantly in the spleen and liver, and within adipose tissue the percentage fell in epididymal white adipose tissue, with numbers per gram of tissue reduced across all three fat depots. Maturation, tracked using the classical CD27 and CD11b staging scheme, was also impaired. Middle-aged mice showed an accumulation of immature CD27-positive single-positive cells and a loss of mature CD11b-positive single-positive cells in the spleen and bone marrow, a pattern resembling that previously described in much older animals. In the fat depots, mature subsets were similarly depleted. Notably, the liver appeared relatively spared, suggesting tissue-specific vulnerability. Broader immune profiling using t-distributed stochastic neighbor embedding showed that other lymphocyte populations were largely unchanged, with the notable exception of increased M1 and M2 macrophages in the spleen, reinforcing that natural killer cells represent a particularly sensitive target of the midlife immune environment.

The receptor landscape of natural killer cells shifted in ways that would be expected to blunt surveillance. In the spleen, the inhibitory receptors KLRG1 and TIGIT were downregulated while Ly49A was upregulated, and the activation marker CD69 along with the immature markers CD117 and CD127 were elevated, consistent with a less differentiated, functionally compromised state. Adipose tissue NK cells displayed their own distinctive receptor changes, with broad upregulation of multiple activating and inhibitory receptors in epididymal fat. Survival analysis helped explain the falling cell counts: splenic natural killer cells from middle-aged mice showed increased Annexin V positivity, indicating heightened apoptosis, alongside reduced Ki-67 expression, a marker of proliferation. Proliferation was also reduced in bone marrow, epididymal fat, and brown fat. Single-cell RNA sequencing of splenic and bone marrow NK cells reinforced the functional picture, revealing downregulation of NK cell activation pathways and upregulation of p53-mediated signaling in middle-aged animals.

Function followed form. When splenocytes or bone marrow cells were challenged ex vivo with MHC class I-deficient target cells such as YAC-1 and RMA-S, natural killer cells from middle-aged mice produced significantly less interferon-gamma and expressed less surface CD107a than those from young controls. The deficit extended deep into the adipose tissue microenvironment: NK cells isolated from epididymal, inguinal, and even brown fat depots showed markedly impaired degranulation and cytokine production. Imaging flow cytometry using the neutral lipid dye Bodipy 493/503 provided a possible mechanistic clue. Natural killer cells from middle-aged mice accumulated more intracellular lipid than those from young mice, with the most pronounced lipid burden observed in cells residing in epididymal white adipose tissue. This finding echoes earlier reports that lipid droplet accumulation inside NK cells can compromise their cytotoxic machinery, and it suggests that a lipid-enriched adipose microenvironment may directly poison the antitumor capacity of these lymphocytes.

To separate the effects of aging from those of obesity itself, the researchers fed 8-week-old young male mice a high-fat diet deriving 60 percent of calories from fat for 16 weeks. These diet-induced obese animals, though young, mirrored many of the NK cell defects seen in their middle-aged counterparts. Splenic and bone marrow natural killer cells showed reduced interferon-gamma production and degranulation upon target cell stimulation, and cells within all three adipose depots displayed the same functional impairment. The authors note that NK cell dysfunction was, if anything, more pronounced in the high-fat diet group than in middle-aged mice, likely because the dietary model produced even greater adipose expansion. Together with previous reports that dietary restriction can enhance NK cell function, this experiment supports the interpretation that excess adiposity itself, independent of chronological age, is a major driver of the immune decline observed in midlife.

The study has limitations that the authors acknowledge. The comparison between middle-aged obesity and diet-induced obesity is indirect and cannot fully disentangle the two conditions, and the focus on male participants and male mice, justified by the far more pronounced weight gain and adipogenesis seen in males during middle age, leaves sex-specific differences in female biology largely unexplored. Nevertheless, the implications are considerable. Epidemiological data indicate that middle-aged adults with obesity face a higher mortality risk than expected for their conditions, and the loss of natural killer cell quantity and surveillance documented here offers a plausible immunological mechanism linking midlife weight gain to increased vulnerability against cancer and infections. Because white adipose tissue is the first organ to show age-related transcriptomic changes beginning in middle age, and because longevity-promoting pathways such as sirtuins and forkhead box proteins typically suppress adipogenesis, the study positions the expanding fat depot not merely as a passive energy store but as an active remodeler of systemic immunity. If confirmed in larger and more diverse cohorts, these findings suggest that maintaining metabolic health through the middle decades could help preserve the innate immune defenses that guard the body against malignancy and viral disease well before old age arrives.

Subject of Research: Natural killer cell dysfunction during midlife obesity in humans and mice

Article Title: Natural Killer Cell Dysfunction Is Emerging During Midlife Obesity

Article References: Biao, R., Wang, X., Fu, J., Guo, Y., He, J., & Du, J. (2026). Natural Killer Cell Dysfunction Is Emerging During Midlife Obesity. Aging Cell, 25(9), Article e70707. https://doi.org/10.1111/acel.70707

Image Credits: AI Generated

DOI: 10.1111/acel.70707

Keywords: natural killer cells, midlife obesity, immune aging, white adipose tissue, interferon-gamma, lipid accumulation, inflammaging, high-fat diet, basal metabolic rate, NK cell maturation, cytotoxicity, Aging Cell

Huntington’s disease is an inherited, progressive brain disorder caused by an expanded CAG repeat in the huntingtin gene. The mutation produces a toxic protein that gradually damages striatal and cortical neurons, giving rise to a characteristic combination of involuntary movements, cognitive decline and psychiatric disturbance. There is currently no therapy that slows the underlying neurodegenerative process; available drugs manage symptoms, chiefly the movement disorder, while the disease continues its course over one to two decades. Against that backdrop, interventions that target the metabolic environment of vulnerable neurons have attracted growing interest, because mounting evidence suggests that mitochondrial dysfunction and altered energy metabolism are central players in the disease process rather than incidental byproducts of it.

The scientific rationale for testing fasting in Huntington’s disease stretches back more than two decades. In 2003, a team led by Wenzhen Duan reported in the Proceedings of the National Academy of Sciences that dietary restriction normalized glucose metabolism and slowed disease progression in a mouse model of the disorder — the first preclinical demonstration that manipulating meal timing could influence the course of Huntington-like pathology. That observation languished in relative obscurity for years, but it seeded a line of research that matured into a comprehensive review published in Translational Neurodegeneration in 2024, in which R. G. Wells, L. E. Neilson, A. W. McHill and A. L. Hiller synthesized the animal evidence on dietary fasting and time-restricted eating in Huntington’s disease and proposed mechanisms through which periodic metabolic stress might protect the fragile neurons that die first in patients.

Those proposed mechanisms converge on a handful of interconnected pathways. Fasting periods activate cellular stress-response programs, including autophagy, the cellular housekeeping system that clears damaged proteins and organelles — a process of particular relevance in Huntington’s disease, where misfolded mutant huntingtin protein accumulates inside neurons. Fasting also promotes mitochondrial biogenesis and improves metabolic flexibility, the capacity of cells to switch between glucose and fatty-acid fuel sources. Impaired glucose metabolism and mitochondrial dysfunction are well documented in the disease, and studies of patient-derived fibroblasts have shown that lower mitochondrial oxygen consumption is associated with an earlier age of motor onset, independent of CAG repeat size. In other words, the bioenergetic state of a patient’s cells appears to help determine how quickly the disease unfolds, raising the possibility that interventions which improve cellular energy handling could shift that trajectory.

Translating that biology into a human trial required answering a practical question first: can people with early-stage Huntington’s disease actually adhere to a compressed eating window, and is the regimen safe for a patient population that often struggles with weight loss, swallowing difficulties and heightened metabolic demand? Patients with Huntington’s disease frequently become cachectic as the disease advances, so any dietary intervention that risks accelerating weight or muscle loss would be a non-starter. The trial protocol, published in PLoS ONE in 2025 by the same group, was designed explicitly to test feasibility and tolerability alongside exploratory signals of efficacy, using a twelve-week interventional design in twenty participants with early-stage disease.

The results, now summarized in Nature Metabolism as a Research Briefing accompanying the full pilot study by Wells and colleagues, indicate that the intervention was feasible and well tolerated across the study period. Participants restricted their eating to a daily window of six to eight hours — a form of intermittent fasting that does not require caloric counting or outright fasting days, only a consistent daily schedule. That operational simplicity matters for clinical translation, because adherence is the perennial Achilles heel of dietary interventions, and regimens that demand extreme restriction rarely survive contact with real-world patient life. The pilot’s central achievement is demonstrating that a meaningful fasting window can be implemented in this population without evident harm.

Beyond tolerability, the exploratory analyses generated signals that will shape the design of larger trials. The researchers observed improvements in clinical measures, in plasma neurofilament light and in cellular bioenergetics. Neurofilament light is a structural protein released into the cerebrospinal fluid and blood when axons are injured, and it has emerged as one of the most informative fluid biomarkers of neurodegeneration across a range of disorders. A five-year longitudinal study published in eBioMedicine in 2024 by G. M. Parkin, E. A. Thomas and J. Corey-Bloom mapped the expected annual rise in plasma neurofilament light across the Huntington’s disease spectrum, providing the reference framework against which the changes observed in the fasting pilot can be interpreted. A biomarker trajectory that bends away from the expected rise over twelve weeks is not proof of neuroprotection, but it is exactly the kind of signal that justifies investing in a definitive trial.

The bioenergetics findings connect the human results back to the mechanistic work in cells and animals. Because mitochondrial respiratory capacity in patient cells has been linked to disease onset and progression, measuring cellular energy metabolism before and after the intervention offers a way to ask whether time-restricted eating changes the fundamental metabolic physiology that theory says it should. The pilot’s exploratory improvements in this domain suggest that the intervention engaged the biology it was designed to target, rather than merely changing eating schedules. Body composition and clinical measures were also tracked, addressing the critical safety question of whether compressed eating windows exacerbate the weight loss that plagues many patients — and the reported tolerability indicates the regimen did not produce overt deterioration over the study period.

Caution remains essential at this stage. A pilot study with twenty participants, no control group described in the available summary and exploratory rather than pre-specified confirmatory analyses cannot establish efficacy, and biomarker fluctuations over twelve weeks can reflect measurement variability, seasonal effects or regression to the mean as easily as biological change. The appropriate reading of the work is as a proof of feasibility and signal generation: the study establishes that the intervention can be delivered, that it appears safe in the short term and that its hypothesized targets — neurodegeneration biomarkers and cellular energy metabolism — move in a direction consistent with benefit. Definitive claims will require randomized, controlled trials with larger cohorts, longer follow-up and adequate statistical power, ideally stratified by disease stage and CAG repeat length.

Even so, the significance of the work extends beyond Huntington’s disease. It represents a template for how metabolic interventions long confined to animal models and healthy-volunteer studies can be brought to neurodegenerative populations with careful attention to their specific vulnerabilities. Fasting-based approaches are being explored in Parkinson’s disease, multiple sclerosis and other neurological conditions, and the Huntington’s pilot provides one of the first direct human data points in a monogenic neurodegenerative disorder, where biomarkers are unusually well characterized and disease progression can be tracked with precision. If larger trials confirm that something as simple as when patients eat — independent of what or how much — can alter the trajectory of a fatal genetic brain disease, the implications for how medicine thinks about meal timing would be profound. For now, the message to patients is one of tempered optimism: the evidence is early, the trials are small, and no one should undertake extended fasting without medical supervision. But the door that Duan’s mice opened in 2003 has now been walked through by human patients, and the field will be watching closely to see what lies on the other side.

Subject of Research: Clinical testing of time-restricted eating as an intermittent fasting intervention in early-stage Huntington's disease

Article Title: Meal timing as medicine: clinical evidence for intermittent fasting in Huntington’s disease

Article References: Meal timing as medicine: clinical evidence for intermittent fasting in Huntington’s disease. (2026). Nature Metabolism. https://doi.org/10.1038/s42255-026-01613-w

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01613-w

Keywords: Huntington's disease, time-restricted eating, intermittent fasting, neurofilament light, mitochondrial bioenergetics, neurodegeneration, pilot study, metabolism, clinical trial, dietary restriction, Nature Metabolism, biomarkers

The authors begin with the supply side. Serum albumin is the most abundant protein in blood plasma, and slaughterhouse blood represents a massive, cheap and largely untapped reservoir of it. Plasma fractionation, a technology refined since the landmark Cohn fractionation work of the 1940s, allows albumin to be separated from other plasma proteins at industrial scale. In medicine, serum albumin is indispensable: it maintains osmotic pressure in the bloodstream, ferries fatty acids, hormones, drugs and metabolites through the circulation, and serves as a biomarker for liver function and inflammation. Recombinant DNA technology now permits production of human serum albumin in yeast and other expression systems, easing supply constraints for pharmaceutical use. But while the biomedical community has thoroughly industrialized the protein, the food industry has been far more hesitant, and the review asks why.

Part of the answer lies in the protein’s remarkable structure. Serum albumin is a single polypeptide chain of roughly 585 amino acids folded into a heart-shaped, three-domain architecture held together by disulfide bridges. This topology gives the protein its famous promiscuity: it possesses multiple hydrophobic pockets that can bind an astonishing range of small molecules. In food systems, that means albumin can sequester and carry bioactive compounds that would otherwise degrade or taste bitter. Studies reviewed by the authors show that bovine serum albumin binds polyphenols such as resveratrol, curcumin, genistein and tea catechins; food colorants like indigo carmine; preservatives such as sodium benzoate and sodium propionate; and flavor compounds including maltol. Each of these interactions has been mapped with spectroscopy, calorimetry and molecular docking, and each suggests a practical application: albumin could act as a natural carrier that protects delicate antioxidants through processing and delivery, then releases them in the gut.

The review’s survey of functional applications begins with emulsions, arguably the most mature arena for albumin in food research. As early as the 1980s, scientists demonstrated that bovine serum albumin is an effective emulsifier, rapidly adsorbing at oil-water interfaces and unfolding to form stabilizing films. Recent work has pushed the concept much further. Albumin stabilized fish oil-in-water emulsions, protecting oxidation-prone omega-3 lipids; it formed soft protein particles when glycated, capable of stabilizing high internal phase emulsions that resemble solid gels while containing mostly oil; and conjugates of albumin with maltodextrin or green tea polysaccharides showed improved emulsifying and antioxidant performance. Ultrasonically engineered albumin nanoparticles have recently been used to build ultra-stable Pickering emulsions, in which solid protein particles cling to droplet surfaces like microscopic armor. In these systems, albumin is not merely a model; it performs on par with the dairy and plant proteins that dominate commercial emulsifier markets.

Foams represent a second frontier, and one where albumin’s properties are particularly striking. Proteins stabilize foams by migrating to air-water interfaces and forming elastic films that resist coalescence, and albumin excels at this. Recent structural work using human serum albumin has revealed, at near-atomic resolution, how the protein reorganizes when it reaches a foam surface, insights that explain its exceptional surface activity. Studies reviewed in the paper show albumin-based nanofibrils with strong emulsifying and foaming activity, and complexes of bovine serum albumin with chitooligosaccharides that have been tested directly in angel food cake, one of the most foam-dependent products in the bakery repertoire. That a blood-derived protein can improve the texture of a familiar dessert illustrates how far the technology has moved beyond abstract model systems.

The review then turns to delivery architectures: nanoparticles and hydrogels. Albumin self-assembles into nanoscale particles under pH-driven, ultrasonic or desolvation methods, and food scientists have loaded these particles with curcumin and resveratrol together, with green tea catechins, or with extracts of Lycium barbarum leaves, consistently reporting enhanced protection and bioavailability of the cargo. Hydrogels formed from albumin, whether through heat-induced aggregation, pH manipulation or the formation of amyloid-like fibrils, offer soft, biocompatible matrices that can encapsulate vitamins and other labile nutrients and release them in a controlled fashion. Additive manufacturing studies have even shown that albumin-based hydrogels and bioplastics can be 3D printed, hinting at personalized nutrition applications in which nutrient-loaded protein scaffolds are printed directly into foods. These systems borrow heavily from the biomedical literature, where albumin hydrogels and nanoparticles are already advanced drug-delivery platforms, and the review makes the case that the food field should keep borrowing.

Perhaps the most topical section of the review concerns cultured meat. Cell-cultivated meat production currently depends heavily on fetal bovine serum, a costly, ethically fraught and poorly defined supplement used to grow muscle cells in bioreactors. Serum albumin is one of the principal functional components of that serum, providing growth factors a stable carrier, buffering capacity and osmotic support. The Chung-Ang University group has itself published studies showing that livestock blood can be processed into fetal bovine serum substitutes and that egg-derived extracts may replace serum components, and other teams have demonstrated serum-free media for bovine satellite cells and fish myoblasts, as well as recombinant albumin produced in Pichia pastoris for serum-free culture. In this context, albumin is not a niche ingredient but a central node in the effort to make cultivated meat affordable, scalable and free of animal-derived serum, one of the biggest bottlenecks facing the entire industry.

So why, despite all this capability, is serum albumin still mainly a model protein in food science rather than a listed ingredient? The review identifies a cluster of consumer-facing barriers. Cultural acceptance is foremost: blood has deep culinary roots in some traditions, from black pudding to blood soups, but in many Western markets the idea of blood-derived ingredients triggers disgust responses that no technical performance can easily overcome. Religious dietary laws, including halal and kosher requirements, impose strict constraints on blood and blood derivatives, effectively excluding the ingredient from entire markets. Dietary trends amplify the problem: the rapid growth of plant-based and vegetarian eating patterns means a growing share of consumers actively avoid animal-sourced proteins, however functional they may be. Then there is allergenicity. Serum albumins are unusual allergens, highly cross-reactive across mammalian species, meaning that a consumer sensitized to, say, cat or dog dander albumin may react to bovine serum albumin in food. Milk and meat products already contain trace albumins that can trigger reactions in sensitive individuals, and adding concentrated albumin to processed foods would raise genuine safety and labeling questions.

The authors do not present these obstacles as a verdict; they present them as an agenda. The review’s forward-looking sections point toward strategies that could defuse each barrier: recombinant and precision-fermentation routes to albumin that decouple the protein from blood; careful processing and formulation that reduce allergenic potential; transparent labeling and consumer research to understand where blood-derived, fermentation-derived and hybrid ingredients might be accepted; and targeted applications where albumin’s unique binding and interfacial properties deliver value that commodity proteins cannot, such as protecting expensive nutraceuticals or enabling serum-free cultured meat media. In a circular economy framing, valorizing slaughterhouse blood also addresses a genuine sustainability problem, converting a waste stream with a heavy environmental footprint into high-value protein.

The broader message of the review is a lesson about how ingredients actually reach our plates. Serum albumin has spent half a century proving itself in emulsions, foams, gels, nanoparticles and cell culture, accumulating an impressive technical dossier along the way. What has been missing is not science but systems thinking: the economics of extraction, the regulations governing novel foods, the allergies and taboos of consumers, and the competitive price of soy, whey and egg proteins. As the food industry races to feed a growing population with less waste, fewer animals and cleaner labels, proteins like serum albumin, sitting unnoticed in an undervalued by-product, may find their moment. The science, as this review makes abundantly clear, has been ready for some time. The remaining challenge is persuading eaters, regulators and manufacturers to take a second look at what flows down the slaughterhouse drain.

Subject of Research: Serum albumin as a functional protein ingredient in food technologies

Article Title: Serum albumin in food technologies: current applications and future perspectives

Article References: Venter, C., Mariano, E., Lee, D.-Y., & Hur, S. J. (2026). Serum albumin in food technologies: current applications and future perspectives. Food Science and Biotechnology. https://doi.org/10.1007/s10068-026-02305-7

Image Credits: AI Generated

DOI: 10.1007/s10068-026-02305-7

Keywords: serum albumin, emulsions, foams, nanoparticles, hydrogels, cultured meat, slaughterhouse blood, ligand binding, allergenicity, Pickering emulsions, food by-products, serum-free media

That suspicion has been fueled by a striking clinical observation. Reduced GLO1 expression has been reported both in experimental models of metabolic dysfunction-associated fatty liver disease, or MAFLD, and in liver biopsies from patients with the condition. MAFLD, driven by excessive fat storage in the liver, is estimated to affect roughly 24 percent of the United States population and is present in more than 70 percent of patients with type 2 diabetes, making it one of the most common and consequential comorbidities of the modern obesity pandemic. Sustained consumption of high-carbohydrate diets, particularly those rich in fructose, is a major driving factor in the pathogenesis of both obesity and MAFLD, and fructose-containing foods are capable of inducing insulin resistance in humans and metabolic syndrome in mice. Yet despite the clear association between diminished GLO1 and fatty liver disease, a fundamental question remained unanswered: is the loss of GLO1 a cause of the disease, or merely a compensatory response to it?

A new study published in Physiological Reports by a team at the University of Arizona set out to resolve this question directly. Rather than merely observing correlations, the researchers generated whole-body Glo1 knockout mice using CRISPR-SpCas9 genome editing in the C57Bl/6NN strain, targeting exon 3 of the Glo1 gene with guide RNAs to produce frameshift deletions through non-homologous end joining. They then challenged these mice, alongside wild-type controls, with sixteen weeks of a high-fat, high-sucrose diet containing 36 percent fat and 30 percent sucrose, a regimen well documented to induce fatty liver disease and impair glucose tolerance. The team’s initial hypothesis was straightforward: if reduced GLO1 expression contributes to MAFLD, then deleting the gene should exacerbate metabolic dysfunction by increasing MGO-mediated stress. What they found instead was a surprise that reshapes how the field should think about the glyoxalase system.

Contrary to expectations, the knockout mice were substantially protected from hepatic fat accumulation. When wild-type mice consumed the obesogenic diet, they developed substantial hepatic steatosis, with triglycerides building up in the liver as expected. In the Glo1-deficient mice fed the same diet, this triglyceride accumulation was significantly blunted. The protection was specific to the liver: adipose tissue biology was largely unaffected, with no significant differences in adipocyte size, epididymal white adipose tissue mass, or markers of fat tissue injury between genotypes under the high-fat, high-sucrose conditions. Serum triglycerides and beta-hydroxybutyrate, a readout of fatty acid oxidation, varied only with diet and not with genotype, suggesting that the hepatic phenotype was not secondary to altered fat export or whole-body fat burning. The findings point toward a previously unrecognized role for GLO1 in directly regulating hepatic lipid metabolism, positioning the enzyme as an unexpected participant in the biology of fatty liver rather than a passive bystander.

But the metabolic ledger did not balance cleanly. While the knockout mice enjoyed relative protection from fatty liver, their systemic glucose handling deteriorated in a diet-dependent manner. Fasting blood glucose was significantly elevated in high-fat, high-sucrose-fed knockout mice compared with their wild-type counterparts. Oral glucose tolerance testing revealed a significant reduction in the ability of knockout mice to clear systemic glucose when compared with chow-fed controls, and although the difference between the two genotypes on the obesogenic diet did not reach statistical significance in the raw tolerance curves, a deeper analysis told a more troubling story. The constant of glucose decay, calculated from insulin tolerance testing as the rate of glucose disappearance, revealed a significant reduction in insulin responsiveness specifically in the high-fat, high-sucrose-fed knockout mice. Notably, serum insulin levels and hepatic insulin signaling, assessed through phosphorylation of the insulin receptor and AKT, showed no significant differences, indicating that the glucose defect operates independently of measurable changes in insulin activity.

To understand the biochemistry underlying these divergent phenotypes, the researchers turned to sensitive mass spectrometry-based quantification of MGO and its downstream molecular footprints. Free hepatic MGO was not significantly elevated in any treatment group, and the product of GLO1 activity, lactoylglutathione, was significantly reduced in the knockout mice, consistent with the loss of enzyme function. A complicating factor emerged, however: the high-fat, high-sucrose diet produced a marked reduction in hepatic glutathione regardless of genotype, and because glutathione is required for GLO1 activity, the reduction in lactoylglutathione may partly reflect this glutathione depletion. When the team examined MGO-derived post-translational modifications on proteins, the results were equally nuanced. Levels of MGO-hydroimidazolone 1, a signature MGO-derived arginine modification, were not significantly affected by diet or genotype, while carboxyethylarginine was elevated in chow-fed knockout mice. These data contradict previous reports indicating dramatic elevations in MGO-derived modifications under diet-induced metabolic stress, and they suggest that steady-state MGO biology in vivo is more buffered than cell culture experiments would predict.

The study also delivered a decisive verdict on a long-standing controversy in diabetes research. Earlier work using short hairpin RNA to knock down Glo1 reported that reduced GLO1 activity could spontaneously generate pathologies resembling diabetic nephropathy in non-diabetic mice, fueling the idea that GLO1 loss is a primary driver of diabetic kidney disease. The Arizona team therefore reasoned that sixteen weeks of high-fat, high-sucrose feeding would exacerbate kidney injury in their knockout animals. Instead, they found no evidence of renal pathology attributable to GLO1 loss. Kidney glycogen accumulated with the obesogenic diet but was unaffected by genotype, serum urea and creatinine were unchanged across all cohorts, and renal levels of MGO-hydroimidazolone 1, carboxyethylarginine, and 3-nitrotyrosine, a modification associated with oxidative stress, showed no significant differences. These findings independently confirm earlier reports from a separate group that complete genetic deletion of Glo1 fails to reproduce the diabetic kidney phenotype seen with knockdown approaches, and they collectively indicate that loss of GLO1 alone is insufficient to drive diabetic nephropathy.

Why might deleting a detoxification enzyme protect the liver while harming glucose control? The authors offer several mechanistic possibilities grounded in their own prior work. In cultured fibroblasts, they previously showed that loss of GLO1 reduces glucose uptake and glycolytic flux, and that Glo1-deficient cells fail to differentiate into mature adipocytes. If a similar reduction in glycolytic flux occurs in the livers of knockout mice in vivo, it would limit the substrate available for MGO generation, potentially explaining why free MGO and MGO-derived modifications remain largely unchanged despite the absence of the primary detoxification enzyme. Reduced glycolytic flux could also directly limit de novo lipogenesis, the pathway by which the liver converts excess carbohydrate into fat, providing a plausible mechanism for the blunted hepatic triglyceride accumulation. Meanwhile, the concept that MGO is not simply a toxin but a concentration-dependent metabolic signal is gaining traction: modest elevations of MGO have been reported to be protective in cardiac ischemia-reperfusion injury and even stimulatory for tumor growth, while only cytotoxic concentrations far exceeding those measured in vivo cause cell death.

The authors are careful to note the limitations of their work. The dietary intervention was terminated at sixteen weeks, a timepoint at which significant hepatic steatosis is evident but more advanced features of MAFLD, such as frank inflammation and fibrosis, have not yet developed. Whether GLO1 influences disease progression at later stages, including the transition to metabolic dysfunction-associated steatohepatitis, remains unknown and is a focus of ongoing investigation. The study also focused on male mice, leaving potential sex differences unexplored, and it did not evaluate alternative MGO detoxification pathways, such as the aldehyde dehydrogenases and aldose reductase, which are thought to play secondary roles but could become important under chronic metabolic stress. Samples for insulin signaling analysis were collected from fed rather than fasted mice, so the effect of GLO1 on glucose-stimulated insulin secretion could not be assessed.

Even with these caveats, the study carries a clear and provocative message: hepatic lipid accumulation and systemic glycemic control are mechanistically distinct in the absence of GLO1, and the glyoxalase system sits at an unexpected crossroads between the two. For a field that has largely treated MGO as a toxic metabolic accident and GLO1 as a straightforward protective enzyme, the demonstration that complete GLO1 loss limits fatty liver while impairing glucose handling in obese male mice demands a more sophisticated view. Future investigations aimed at deciphering the tissue-specific roles of GLO1 in whole-body glucose tolerance and lipid metabolism may reveal whether the glyoxalase cycle, long relegated to the footnotes of biochemistry textbooks, holds therapeutic potential for one of the most common liver diseases of our time.

Subject of Research: The role of glyoxalase 1 in obesity-associated fatty liver disease, glucose homeostasis, and kidney health in mice.

Article Title: Glyoxalase 1 loss reduces fatty liver but impairs glucose handling in male mice

Article References: Hoffman, E. A., Phoebe, A. M., Trujillo, M. N., Zhang, W. C., Jennings, E. Q., Farrera, D. O., Orlicky, D. J., Rutt, L. N., McCullough, R. L., Huacachino, A. A., Marcinkiewicz, M. M., Snyder, N. W., Bruner, K. R., Payan, K. B., Martinez, D. J. F., Stern, J. H., & Galligan, J. J. (2026). Glyoxalase 1 loss reduces fatty liver but impairs glucose handling in male mice. Physiological Reports, 14(17), Article e71106. https://doi.org/10.14814/phy2.71106

Image Credits: AI Generated

DOI: 10.14814/phy2.71106

Keywords: glyoxalase 1, methylglyoxal, fatty liver disease, MAFLD, glucose tolerance, hepatic triglycerides, glyoxalase cycle, high-fat high-sucrose diet, diabetic nephropathy, glycolysis, post-translational modifications, knockout mice

The investigation began with a deceptively simple behavioral question: given a choice, do mosquitoes prefer well-fed or undernourished hosts? Using controlled dietary restriction in laboratory mice, the researchers ran paired preference assays with multiple medically important mosquito species and found a consistent and striking result. Female mosquitoes preferentially oriented toward and fed on the undernourished animals. Because host-seeking in mosquitoes is governed by a layered integration of sensory cues, including carbon dioxide, heat, humidity, vision, and above all odor, the team reasoned that nutritional status might be altering the volatile chemical signature that hosts emit into the air. Behavioral experiments in which cues were selectively masked or manipulated confirmed that the differential attraction was olfactory in nature, pointing the investigators toward the skin surface as the source of the signal.

Gas chromatography-mass spectrometry analysis of volatile emissions from the skin of undernourished mice revealed a specific chemical culprit: elevated levels of volatile aldehydes. When these aldehydes were presented to mosquitoes in isolation or applied to otherwise unattractive hosts, they acted as potent attractants, reproducing the preference pattern observed with live undernourished animals. The aldehydes were not produced by the hosts themselves. Instead, they emerged from an unexpected intermediate player, the community of commensal bacteria that colonizes the skin. Sequencing and culture-based analyses showed that undernutrition was associated with a marked dysbiosis of the skin microbiota, with certain bacterial taxa proliferating to excessive densities and shifting their metabolic output toward aldehyde production. In effect, the mosquito-attractive odor was a microbial byproduct, released in greater quantities whenever the host’s nutritional state deteriorated.

The next question was mechanistic: why would a poor diet destabilize the skin microbiome in the first place? The answer lay in the dermal sebaceous glands, the microscopic structures that secrete sebum, a lipid-rich film coating the outer skin. The researchers found that undernutrition impaired the secretion of free fatty acids from these glands. Free fatty acids are not merely structural components of the skin barrier; they possess well-documented antimicrobial activity, suppressing the overgrowth of bacteria on the surface. With fatty acid output diminished, this chemical shield weakened, and commensal skin bacteria expanded unchecked. The team demonstrated this causal chain experimentally: restoring antimicrobial fatty acids, or reducing bacterial loads with antibiotics, both reversed the microbiota expansion and abolished the excess aldehyde emissions, thereby eliminating the heightened attractiveness of undernourished mice to mosquitoes.

To rule out confounding factors such as fur and general husbandry, the researchers extended their experiments to SKH1 hairless mice, in which skin surface chemistry can be sampled directly. The same pattern held. Undernutrition drove sebaceous dysfunction, skin bacterial overgrowth, dysbiosis, elevated aldehyde production, and increased mosquito attraction, providing a clean replication of the mechanism in a model system where the skin itself is fully accessible to analysis. The authors also showed that the effect operates in both directions of the transmission cycle. Undernourished mice were not only more likely to be bitten; they were also more susceptible to infection with dengue virus (DENV), developing higher viral loads. When mosquitoes fed on these viremic, undernourished hosts, the insects acquired virus more efficiently, and when infected mosquitoes subsequently fed, transmission onward was enhanced.

This dual effect, increasing both the probability that a host infects a mosquito and the probability that an infected mosquito infects a host, is what gives the finding its epidemiological weight. Vector-borne pathogens depend on a chain of events, each of which carries a probability, and interventions that raise or lower any single link can have outsized effects on the reproduction of an epidemic. By strengthening two links at once, host attractiveness and host infectivity, undernutrition may function as a critical modulator of transmission efficacy at the population level. The researchers present a model in which the prevalence of undernourished individuals within a community critically shapes the intensity of arbovirus circulation, a proposition with obvious implications for the geography of disease burden.

The human relevance of the mechanism was tested directly. In a cohort of undernourished human subjects, the team documented skin microbiota alterations mirroring those seen in mice, alongside elevated emission of volatile aldehydes from the skin. In behavioral assays, undernourished participants were more attractive to mosquitoes than their well-nourished counterparts. These converging lines of evidence, spanning rodent models, chemical analytics, microbiology, and human physiology, elevate the study beyond a correlation and support a coherent biological narrative: caloric and nutritional insufficiency suppresses sebaceous antimicrobial output, permits bacterial overgrowth, changes the skin’s volatile signature, and rewires the chemical conversation between humans and mosquitoes.

The broader context is sobering. Undernutrition and mosquito-borne disease overlap extensively across the tropics and subtropics, where food insecurity, poverty, and endemic dengue, malaria, Zika, and other arboviruses co-occur. Earlier work from the same field had established that host nutritional status can influence arbovirus virulence and evolution, and that host serum iron modulates dengue virus acquisition by mosquitoes, indicating that diet intersects with vector-borne transmission at multiple physiological levels. The new study adds skin chemistry and microbiota to this list and identifies a targetable axis. If aldehyde emissions and bacterial overgrowth mediate the effect, then interventions that restore sebaceous antimicrobial lipids, modulate the skin microbiome, or neutralize aldehyde cues could, in principle, reduce the excess bite risk borne by malnourished individuals, complementing bed nets, repellents, and vaccines.

For public health planners, the message is that nutritional support programs may double as disease control programs. Addressing undernutrition in regions where mosquito-borne pathogens are endemic would not only alleviate the direct morbidity and mortality of deficiency itself, but could also dampen the transmission cycles that keep those pathogens circulating. The authors argue that undernutrition should be recognized as a key driver of mosquito-borne disease transmission in nature, a reframing that places nutrition squarely within the toolkit of vector-borne disease control. As climate change expands the range of Aedes and Anopheles vectors and as food insecurity persists or worsens in many endemic regions, understanding and disrupting the metabolic link between diet, skin microbiota, and mosquito behavior may prove essential to bending the curves of some of the world’s most persistent epidemics.

Subject of Research: How undernutrition increases host attractiveness to mosquitoes and promotes the transmission of mosquito-borne diseases through skin microbiota changes.

Article Title: Undernutrition enhances host attractiveness to mosquitoes and transmission of mosquito-borne diseases

Article References: Wang, M., Song, X., Zhu, Y., Niu, J., Wang, G., Wang, Y., Xiao, H., Lei, D., Wu, T., Liu, L., Wang, P., Wang, J., & Cheng, G. (2026). Undernutrition enhances host attractiveness to mosquitoes and transmission of mosquito-borne diseases. Cell Research. https://doi.org/10.1038/s41422-026-01291-z

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01291-z

Keywords: undernutrition, mosquito-borne diseases, dengue virus, skin microbiota, volatile aldehydes, sebaceous glands, fatty acids, host-seeking behavior, arboviruses, vector biology, malnutrition, disease transmission

The study, conducted within the Brazilian Unified Health System and reported according to STROBE guidelines, followed 111 caregiver–child dyads recruited through consecutive sampling between 2021 and 2023. Children and adolescents aged 8 to 16 years were eligible if they had a prior diagnosis of obesity, defined as a BMI z-score of 2 or higher under World Health Organization criteria, and medical clearance for regular physical activity. Caregivers, the vast majority of whom were mothers—83.8 percent of the sample—had to live in the same household and attend the child’s follow-up visits. Crucially, the researchers implemented no experimental intervention. Every appointment, assessment, and educational encounter followed the clinic’s existing protocol, making this a portrait of obesity care as it is actually delivered in a resource-constrained public system rather than as it might be delivered in an idealized research setting.

The clinical routine began with a mandatory 90-minute educational session delivered by the multidisciplinary team, introducing families to healthy eating, physical activity, hydration, adequate sleep, and screen-time limits based on Brazilian national guidelines. Families then returned within a month for multidisciplinary evaluations involving pediatricians, physical educators, and nutritionists, with follow-up frequency varying from one to three months according to clinical need. At baseline, the children presented with severe obesity: a median BMI z-score of 3.13, a median BMI of about 30.1 kg/m², and a mean age of 12.1 years. Nearly 61 percent were boys. The comorbidity burden was already substantial—21.6 percent of the children had hypertension, alongside notable rates of asthma, hepatic steatosis, anxiety, and insulin resistance—and their caregivers were hardly healthier, with 40.5 percent reporting hypertension and 23.4 percent diabetes, and a median caregiver BMI of 32.0 kg/m².

Using quantile mixed-effects regression adjusted for sex and age, the team tracked anthropometric and behavioral changes at three and six months. The results were modest but statistically meaningful in the short term. Children’s BMI z-score fell by 0.1 at three months, a significant reduction, and body fat percentage declined by 0.4 percentage points over the same period. By six months, however, the momentum faded: the BMI z-score change shrank to a non-significant 0.04, and the improvement in body fat was no longer sustained. In a cohort this severely affected, the researchers caution against dismissing even small shifts, since stabilization or slight decreases in BMI trajectories have been linked to improvements in cardiometabolic risk profiles in other studies. Still, the trajectory of the data itself—an early dip that flattens—tells a story about the limits of low-contact care.

The behavioral picture was even more static. Across the entire follow-up, light physical activity, moderate-to-vigorous physical activity, screen time, and sleep duration showed no significant variation. At baseline, the median child reported four hours of daily screen time and a median of zero minutes of moderate-to-vigorous physical activity per week—figures that barely budged. In the dietary domain, one variable did move: water intake increased modestly and significantly at both assessments, rising by roughly 0.2 liters per day at three months and 0.1 liters at six months. Total caloric intake and sugary beverage consumption remained flat. The researchers interpret this pattern as evidence that standardized guidance at program entry, plus individualized counseling during follow-up, may raise awareness but is rarely sufficient on its own to disrupt well-established behavioral patterns, particularly among socially vulnerable families facing structural and environmental barriers to change.

Perhaps the most striking finding concerned the caregivers. Despite the consistent evidence from intensive family-based intervention programs that child weight reduction often travels with parental weight change, caregiver body composition in this real-world cohort remained remarkably stable across all six months. Weight, waist circumference, BMI, and body fat percentage showed no significant longitudinal variation. Meanwhile, the cross-sectional correlation between caregiver and child BMI stayed moderate and consistent at every time point—0.293 at baseline, 0.274 at three months, and 0.304 at six months—confirming that families share weight profiles. Yet when the researchers examined whether changes moved together, the synchronization dissolved: changes in pediatric BMI z-score were not significantly correlated with changes in caregiver BMI over time, with a Spearman coefficient of just 0.134. In other words, caregivers and children started from similar places, but they did not travel together.

A responder analysis sharpened that insight. Among the 99 dyads with complete follow-up data, 49.5 percent were classified as responders, having achieved a reduction in BMI z-score of at least 0.1 at six months. The single factor distinguishing responders was age: responders were significantly younger, averaging 11.5 years versus 12.5 years for non-responders, a small-to-moderate effect. Baseline caregiver BMI did not differ between the groups. This points to an early window—before obesity becomes deeply entrenched—as the most favorable period for behavioral adaptation, and it suggests that by the time children reach tertiary care with severe, long-standing obesity, the condition is sustained by an interlocking web of behavioral, environmental, and biological mechanisms. Neuroendocrine adaptations and genetic predisposition can elevate the biological set point and blunt responsiveness to lifestyle-based approaches, while emotional eating—using food to cope with stress or distress—may further undermine behavioral guidance.

The authors are careful to frame these findings not as a failure of clinicians but as an expected output of a pragmatic care model. Compared with structured, high-contact family-based behavioral treatments, which have demonstrated stronger results in trials and primary-care implementations, the routine care evaluated here involved variable consultation frequency and few structured behavioral components. Knowledge-transfer strategies, the evidence suggests, rarely produce sustained lifestyle change without ongoing behavioral support, especially in populations contending with food insecurity, financial constraints, and limited access to safe spaces for physical activity. The stability of caregiver BMI throughout follow-up implies that the shared household routines and environmental constraints shaping the child’s behavior persisted largely untouched, potentially capping the effectiveness of recommendations aimed at the child alone.

The study’s limitations are those inherent to real-world observational designs: no comparison group, a short six-month window, a sample sized by clinic flow, losses to follow-up among 12 dyads, and no socioeconomic data. The findings also cannot isolate the effect of the initial educational session from the surrounding multidisciplinary care. Even so, the takeaway is clear and actionable. Routine multidisciplinary care in this public setting may help prevent further deterioration in children with severe obesity, but achieving substantial improvement will demand more: structured behavioral components, increased contact frequency, active engagement of caregivers as agents of change, stronger early detection and prevention in primary care, and consistent implementation of the public policies Brazil already has on paper. As childhood obesity continues to climb, the gap between what clinics can do alone and what families and health systems must do together has rarely been drawn in sharper relief.

Subject of Research: Longitudinal changes in pediatric obesity and caregiver-child BMI associations during routine multidisciplinary outpatient care

Article Title: Family Dynamics and Longitudinal Trends in Pediatric Obesity: A Real‐World Observational Study in a Public Outpatient Clinic

Article References: de Freitas, F., da Paz, M. M., Zago, M. R., Vitolo, M. R., Antônio, M. Â., & Brandão, M. Â. B. (2026). Family Dynamics and Longitudinal Trends in Pediatric Obesity: A Real‐World Observational Study in a Public Outpatient Clinic. Obesity Science & Practice, 12(5), Article e70192. https://doi.org/10.1002/osp4.70192

Image Credits: AI Generated

DOI: 10.1002/osp4.70192

Keywords: pediatric obesity, BMI z-score, family dynamics, caregiver-child dyads, multidisciplinary care, observational study, public health, lifestyle behaviors, adolescent health, Brazil, real-world evidence, weight management

The study, led by Nazanin Jabbarzadeh and colleagues, stands out in a crowded field for the care it took with quality control. Microplastic research has been criticized for inconsistent methods, missing blanks, and questionable identifications, so the team built their workflow around safeguards. They processed five procedural blanks per batch, exposed blank filters to laboratory air during each filtration session, pre-filtered all reagents through 0.45 micrometer membranes, and wore cotton lab coats and nitrile gloves inside a laminar flow hood to minimize airborne contamination. Procedural blanks averaged just 1.2 particles per filter and airborne blanks 0.6, yielding a detection threshold of 3.6 particles per filter, well below the lowest sample concentration recorded.

Each one-liter milk sample was digested with 30 percent hydrogen peroxide at 60 degrees Celsius for 24 hours, then vacuum-filtered through 1.2 micrometer glass fiber filters. To gauge how much material the method might lose along the way, the researchers ran spike experiments, adding known quantities of standard microplastic particles to ultrapure water and processing them exactly like samples. Recovery rates ranged from 82 percent for polyethylene terephthalate to 96 percent for polyethylene, with an overall mean of 89 percent. The team then corrected reported concentrations using these polymer-specific recovery factors. They are careful to note, however, that because the spikes were performed in water rather than milk, the recovery figures do not amount to a complete matrix-matched validation of the method for the dairy matrix itself.

Microscopic screening under a stereo microscope at 40 and 100 times magnification recorded 551 particles across all 30 samples. Morphologically, the haul was dominated by fragments, which made up 58 percent of the total, followed by fibers at 35 percent and spheres at 7 percent. Fibers were mostly blue or transparent, while fragments displayed a broader palette including black and red. Three trained analysts counted particles independently for each filter, with the mean recorded to limit observer bias, and systematic grid patterns prevented double-counting. Critically, the authors treat visual examination as a screening step only, not as definitive evidence of polymer identity, a distinction that has often been blurred in earlier microplastic studies of food.

To firm up the chemistry, roughly 150 particles, five per sample, were subjected to scanning electron microscopy coupled with energy-dispersive X-ray spectroscopy, or SEM-EDS. Gold-palladium sputter-coated particles were imaged at accelerating voltages of 15 kilovolts and magnifications up to 10,000 times, revealing surface textures and elemental fingerprints. A polyethersulfone particle, for instance, showed a telltale sulfur peak in its EDS spectrum, while polyethylene particles were dominated by carbon. But elemental composition alone cannot settle polymer identity, so the particles were then interrogated with micro-Raman spectroscopy using a 785 nanometer laser, with spectra matched against reference libraries and custom standards of seven common polymers.

The Raman analysis succeeded for 142 of the 150 particles, a confirmation rate of 94.7 percent, with hit quality indices averaging 0.92. Polyethylene emerged as the most abundant polymer at 32 percent of identified particles, followed by polypropylene at 24 percent, PET at 15 percent, polyamide at 12 percent, and polyethersulfone at 9 percent, with the remaining 8 percent unidentified or other. That profile is striking because polyethylene and polypropylene are precisely the polymers most common in plastic milk bottles and food-contact materials, while polyamide and PET are characteristic of Tetra Pak laminates. The authors caution, however, that polymer identity alone cannot pinpoint where each particle originated.

The statistical centerpiece of the study is the packaging comparison. Milk sold in plastic bottles contained an average of 24.6 particles per liter, roughly double the 12.2 particles per liter found in Tetra Pak cartons, a difference that was highly significant. In a multiple linear regression model, packaging type was the only meaningful predictor of contamination, explaining nearly half the variance in concentrations, while fat content and brand showed no significant effects. Adding product volume to the comparison erased the statistical difference, and the authors are explicit that the observational design of the study establishes an association with packaging, not proof that bottles are the direct source of the particles.

Perhaps most consequential for exposure assessment is the size distribution. SEM measurements of 350 particles yielded a mean longest dimension of 68.4 micrometers, with a pronounced peak between 20 and 50 micrometers. Fully 72 percent of measured particles were smaller than 100 micrometers, and 41 percent smaller than 50. This matters because smaller particles are considered more capable of crossing biological barriers and being taken up by cells, although the authors stress that their study measured particle characteristics only and did not investigate uptake, tissue distribution, or any toxicological outcomes. No health risk conclusions can be drawn from these data alone, they emphasize, and milk consumption should not be regarded as a demonstrated health hazard on this evidence.

The study also fills a geographic gap. Most foodborne microplastic data come from Europe, the Americas, and East Asia, while regions such as Iran have been thinly covered despite prior reports of microplastics in milk, milk powder, and infant formula elsewhere. The authors call for larger and more geographically diverse sampling, process-line monitoring inside dairies, controlled packaging-release experiments, and matrix-matched validation of analytical methods, alongside standardized protocols that would make cross-study comparisons meaningful. For regulators, the results argue for routine microplastic surveillance in dairy; for producers, for tighter quality control across processing, storage, and filling. For consumers, the takeaway is sobering but measured: microplastics are now documented in commercial milk, plastic packaging shows the strongest association, and the science of what that means for human health remains an open and urgent question.

Subject of Research: Microplastic contamination and polymer identification in commercial milk using SEM-EDS and micro-Raman spectroscopy

Article Title: Microplastic Contamination in Commercial Milk: Quantification and Polymer Identification Using SEM-EDS and Micro-Raman Spectroscopy

Article References: Microplastic Contamination in Commercial Milk: Quantification and Polymer Identification Using SEM-EDS and Micro-Raman Spectroscopy. (n.d.). https://doi.org/10.1016/j.crfs.2026.101571

Image Credits: AI Generated

DOI: 10.1016/j.crfs.2026.101571

Keywords: microplastics, milk, food safety, polymer identification, Raman spectroscopy, SEM-EDS, packaging, plastic bottles, Tetra Pak, dairy products, dietary exposure, Iran